BRPI0507847A - processo para a preparação de um composto, e, composto - Google Patents

processo para a preparação de um composto, e, composto

Info

Publication number
BRPI0507847A
BRPI0507847A BRPI0507847-4A BRPI0507847A BRPI0507847A BR PI0507847 A BRPI0507847 A BR PI0507847A BR PI0507847 A BRPI0507847 A BR PI0507847A BR PI0507847 A BRPI0507847 A BR PI0507847A
Authority
BR
Brazil
Prior art keywords
compound
preparing
formulas
compounds
Prior art date
Application number
BRPI0507847-4A
Other languages
English (en)
Inventor
Margaret Anne Butlin
Roger John Butlin
Philip John Hogan
Andreas Meudt
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of BRPI0507847A publication Critical patent/BRPI0507847A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pyridine Compounds (AREA)

Abstract

PROCESSO PARA A PREPARAçãO DE UM COMPOSTO, E, COMPOSTO é decrito um processo para preparar os compostos das fórmulas (I) e (IV)
BRPI0507847-4A 2004-02-20 2005-02-17 processo para a preparação de um composto, e, composto BRPI0507847A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0403744.6A GB0403744D0 (en) 2004-02-20 2004-02-20 Chemical process
PCT/GB2005/000567 WO2005080403A2 (en) 2004-02-20 2005-02-17 Chemical process

Publications (1)

Publication Number Publication Date
BRPI0507847A true BRPI0507847A (pt) 2007-07-10

Family

ID=32040047

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0507847-4A BRPI0507847A (pt) 2004-02-20 2005-02-17 processo para a preparação de um composto, e, composto

Country Status (31)

Country Link
US (2) US7626020B2 (pt)
EP (3) EP2135873B1 (pt)
JP (2) JP2007523906A (pt)
KR (2) KR101196111B1 (pt)
CN (1) CN1922193B (pt)
AR (1) AR047810A1 (pt)
AT (1) ATE535532T1 (pt)
AU (1) AU2005214138B2 (pt)
BR (1) BRPI0507847A (pt)
CA (1) CA2555554A1 (pt)
CL (1) CL2011003138A1 (pt)
CY (1) CY1112555T1 (pt)
DK (1) DK2135873T3 (pt)
ES (1) ES2375201T3 (pt)
GB (1) GB0403744D0 (pt)
HR (1) HRP20120031T1 (pt)
IL (2) IL177505A (pt)
MY (1) MY142268A (pt)
NO (1) NO20064012L (pt)
PL (1) PL2135873T3 (pt)
PT (1) PT2135873E (pt)
RS (1) RS52300B (pt)
RU (1) RU2386636C2 (pt)
SA (1) SA05260017B1 (pt)
SG (1) SG153856A1 (pt)
SI (1) SI2135873T1 (pt)
TW (1) TWI347947B (pt)
UA (1) UA83418C2 (pt)
UY (1) UY28754A1 (pt)
WO (1) WO2005080403A2 (pt)
ZA (1) ZA200606579B (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0219660D0 (en) 2002-08-23 2002-10-02 Astrazeneca Ab Therapeutic use
JO3598B1 (ar) 2006-10-10 2020-07-05 Infinity Discovery Inc الاحماض والاسترات البورونية كمثبطات اميد هيدروليز الحامض الدهني
EP2079734A1 (en) * 2006-10-25 2009-07-22 NeuroSearch A/S Oxadiazole and thiadiazole compounds and their use as nicotinic acetylcholine receptor modulators
TW201000107A (en) * 2008-04-09 2010-01-01 Infinity Pharmaceuticals Inc Inhibitors of fatty acid amide hydrolase
CA2757622A1 (en) 2009-04-07 2010-10-14 Infinity Pharmaceuticals, Inc. Inhibitors of fatty acid amide hydrolase
WO2010118155A1 (en) 2009-04-07 2010-10-14 Infinity Pharmaceuticals, Inc. Inhibitors of fatty acid amide hydrolase
MX361692B (es) 2010-02-03 2018-12-13 Infinity Pharmaceuticals Inc Inhibidores de amida hidrolasa de ácido graso.
CN102491973A (zh) * 2011-12-15 2012-06-13 南京友杰医药科技有限公司 Zd-4054的合成方法
DK3362462T3 (da) 2015-10-12 2021-10-11 Advanced Cell Diagnostics Inc In situ-detektion af nukleotidvarianter i prøver med højt støjniveau, og sammensætninger og fremgangsmåder relateret dertil

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5591761A (en) 1993-05-20 1997-01-07 Texas Biotechnology Corporation Thiophenyl-, furyl-and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
US5514691A (en) * 1993-05-20 1996-05-07 Immunopharmaceutics, Inc. N-(4-halo-isoxazolyl)-sulfonamides and derivatives thereof that modulate the activity of endothelin
US5464853A (en) * 1993-05-20 1995-11-07 Immunopharmaceutics, Inc. N-(5-isoxazolyl)biphenylsulfonamides, N-(3-isoxazolyl)biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin
TW270116B (pt) 1991-04-25 1996-02-11 Hoffmann La Roche
RU2086544C1 (ru) 1991-06-13 1997-08-10 Хоффманн-Ля Рош АГ Бензолсульфонамидные производные пиримидина или их соли, фармацевтическая композиция для лечения заболеваний, связанных с активностью эндотелина
TW224462B (pt) 1992-02-24 1994-06-01 Squibb & Sons Inc
NZ247440A (en) 1992-05-06 1995-04-27 Squibb & Sons Inc Phenyl sulphonamide derivatives, preparation and pharmaceutical compositions thereof
US5965732A (en) 1993-08-30 1999-10-12 Bristol-Myers Squibb Co. Sulfonamide endothelin antagonists
FR2711368B1 (fr) * 1993-09-16 1996-01-05 Roussel Uclaf Nouveau procédé de préparation de dérivés soufrés de l'imidazole et les nouveaux intermédiaires obtenus.
US6063911A (en) 1993-12-01 2000-05-16 Marine Polymer Technologies, Inc. Methods and compositions for treatment of cell proliferative disorders
GB9504854D0 (en) 1994-03-31 1995-04-26 Zeneca Ltd Nitrogen derivatives
GB9409618D0 (en) 1994-05-13 1994-07-06 Zeneca Ltd Pyridine derivatives
AU3642795A (en) 1994-09-27 1996-04-19 Merck & Co., Inc. Endothelin receptor antagonists for the treatment of emesis
GB2295616A (en) 1994-12-01 1996-06-05 Zeneca Ltd N-Diazine-benzenesulphonamide derivatives as endothelin receptor antagonists
US5760038A (en) * 1995-02-06 1998-06-02 Bristol-Myers Squibb Company Substituted biphenyl sulfonamide endothelin antagonists
UA58494C2 (uk) * 1995-06-07 2003-08-15 Зенека Лімітед Похідні n-гетероарилпіридинсульфонаміду, фармацевтична композиція, спосіб одержання та спосіб протидії впливам ендотеліну
GB9512697D0 (en) 1995-06-22 1995-08-23 Zeneca Ltd Heterocyclic compounds
US5780435A (en) * 1995-12-15 1998-07-14 Praecis Pharmaceuticals Incorporated Methods for treating prostate cancer with LHRH-R antagonists
GB9704762D0 (en) * 1997-03-07 1997-04-23 Zeneca Ltd Chemical process
AU3011299A (en) 1998-03-23 1999-10-18 Merck & Co., Inc. Combination therapy for the treatment of benign prostatic hyperplasia
TR200003166T2 (tr) 1998-04-29 2001-02-21 Osi Pharmaceuticals, Inc. N-(3-etinilfenilamino)-6, 7-bis(2-metoksietoksi)-4-kuinozolamin mesilat anhidrat ve monohidrat.
US6673832B1 (en) 1998-05-04 2004-01-06 Gudarz Davar Methods for identifying compounds for treating pain
US6355678B1 (en) * 1998-06-29 2002-03-12 Parker Hughes Institute Inhibitors of the EGF-receptor tyrosine kinase and methods for their use
ATE457169T1 (de) 1998-10-15 2010-02-15 Imp Innovations Ltd Verbindungen für die behandlung von gewichtsverlust
DE19857765A1 (de) * 1998-12-15 2000-06-21 Clariant Gmbh Verfahren zur Herstellung von para-Oxadiazolyl-phenyl-boronsäuren
US7566452B1 (en) 1999-05-04 2009-07-28 New York University Cancer treatment with endothelin receptor antagonists
US6545048B1 (en) 1999-06-29 2003-04-08 California Institute Of Technology Compositions and methods of treating cancer using compositions comprising an inhibitor or endothelin receptor activity
DE60030764T2 (de) 1999-12-15 2007-09-13 Bristol-Myers Squibb Co. Biphenyl - sulfonamide als duale angiotensin - endothelin - rezeptor - antagonisten
ATE348617T1 (de) 2000-02-16 2007-01-15 Astellas Pharma Inc Heilmittel gegen durch endothelin verursachte erkrankungen
WO2001091736A2 (en) 2000-05-31 2001-12-06 Warner-Lambert Company Combinations of an endothelin receptor antagonist and an antiepileptic compound having pain alleviating properties or analgesic
US20020055457A1 (en) * 2000-08-07 2002-05-09 Janus Todd J. Methods of treating cancer and the pain associated therewith using endothelin antagonists
TWI306760B (en) 2000-08-07 2009-03-01 Abbott Lab Use of an endothelin et-a receptor antagonist and orally delivered pharmaceutical composition comprising the same
DE10113366A1 (de) 2001-03-20 2002-09-26 Boehringer Ingelheim Pharma Neue Arzneimittelkompositionen auf der Basis von Anticholinergika und Endothelinantagonisten
DE10059418A1 (de) * 2000-11-30 2002-06-20 Aventis Pharma Gmbh Ortho, meta-substituierte Bisarylverbindungen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
WO2002049630A2 (en) 2000-12-21 2002-06-27 Bristol-Myers Squibb Company Method for preventing or treating pain by administering an endothelin antagonist
KR20040052489A (ko) 2001-03-06 2004-06-23 셀러지 파마세우티칼스, 인크 비뇨생식기 장애 치료용 화합물 및 그 방법
GB0108689D0 (en) 2001-04-05 2001-05-30 Medical Res Council Neuropathologies associated with expression of TNF-a
PE20021032A1 (es) 2001-04-11 2002-11-12 Abbott Lab Composicion farmaceutica para uso en la modulacion favorable de la calidad de vida relacionada con la salud y progresion temporal ajustada a la calidad relacionada con la salud de una enfermedad en pacientes con cancer de prostata
US20030092757A1 (en) * 2001-04-11 2003-05-15 Amitabh Singh Favorable modulation of health-related quality of life and health-related quality-adjusted time-to-progression of disease in patients with prostate cancer
WO2003006041A1 (fr) 2001-07-12 2003-01-23 Takeda Chemical Industries, Ltd. Agents prophylactiques/therapeutiques contre les tumeurs malignes
WO2003009805A2 (en) 2001-07-23 2003-02-06 Brigham And Women's Hospital, Inc. Analgesic methods using endothelin receptor ligands
SE0102616D0 (sv) * 2001-07-25 2001-07-25 Astrazeneca Ab Novel compounds
EP1411933A1 (en) * 2001-08-03 2004-04-28 SmithKline Beecham Corporation Alpha-ketoamide derivatives as cathepsin k inhibitors
DE60239207D1 (de) 2001-08-10 2011-03-31 Takeda Pharmaceutical Gnrh-agonistische kombinationsmittel
DE10155076A1 (de) * 2001-11-09 2003-05-22 Merck Patent Gmbh Verwendung von Endothelin-Rezeptor-Antagonisten zur Behandlung von Tumorerkrankungen
US7973064B2 (en) 2001-11-27 2011-07-05 The Board Of Trustees Of The University Of Illinois Method and composition for potentiating an opiate analgesic
GB0219660D0 (en) 2002-08-23 2002-10-02 Astrazeneca Ab Therapeutic use
GB0223367D0 (en) 2002-10-09 2002-11-13 Astrazeneca Ab Therapeutic treatment
GB0223854D0 (en) 2002-10-12 2002-11-20 Astrazeneca Ab Therapeutic treatment
GB0320806D0 (en) 2003-09-05 2003-10-08 Astrazeneca Ab Therapeutic treatment
ATE507220T1 (de) 2003-12-20 2011-05-15 Merck Patent Gmbh Tetrahydropyranochinolinderivate
GB0425854D0 (en) 2004-11-25 2004-12-29 Astrazeneca Ab Therapeutic treatment
GB0514743D0 (en) 2005-07-19 2005-08-24 Astrazeneca Ab Salt

Also Published As

Publication number Publication date
RU2386636C2 (ru) 2010-04-20
JP2007523906A (ja) 2007-08-23
EP1718655A2 (en) 2006-11-08
IL177505A (en) 2010-12-30
AU2005214138B2 (en) 2009-02-12
UY28754A1 (es) 2005-09-30
TW200538451A (en) 2005-12-01
ZA200606579B (en) 2008-01-30
PL2135873T3 (pl) 2012-03-30
ES2375201T3 (es) 2012-02-27
KR20060129483A (ko) 2006-12-15
SA05260017B1 (ar) 2008-07-14
RS52300B (sr) 2012-12-31
HK1139689A1 (en) 2010-09-24
IL194709A (en) 2010-12-30
RU2006133455A (ru) 2008-03-27
AU2005214138A1 (en) 2005-09-01
AR047810A1 (es) 2006-02-22
PT2135873E (pt) 2012-01-16
CA2555554A1 (en) 2005-09-01
CY1112555T1 (el) 2016-02-10
SG153856A1 (en) 2009-07-29
KR20120036998A (ko) 2012-04-18
EP2325189A2 (en) 2011-05-25
IL177505A0 (en) 2006-12-10
GB0403744D0 (en) 2004-03-24
EP2325189A3 (en) 2011-10-26
EP2135873B1 (en) 2011-11-30
CN1922193A (zh) 2007-02-28
US20100094010A1 (en) 2010-04-15
TWI347947B (en) 2011-09-01
WO2005080403A2 (en) 2005-09-01
ATE535532T1 (de) 2011-12-15
KR101196111B1 (ko) 2012-10-30
US7626020B2 (en) 2009-12-01
CN1922193B (zh) 2012-12-26
WO2005080403A3 (en) 2005-11-24
NO20064012L (no) 2006-11-06
SI2135873T1 (sl) 2012-03-30
EP2135873A3 (en) 2010-03-24
UA83418C2 (uk) 2008-07-10
DK2135873T3 (da) 2012-02-13
US20080161565A1 (en) 2008-07-03
HRP20120031T1 (hr) 2012-02-29
CL2011003138A1 (es) 2012-06-22
MY142268A (en) 2010-11-15
EP2135873A2 (en) 2009-12-23
JP2012031174A (ja) 2012-02-16

Similar Documents

Publication Publication Date Title
BRPI0318811B8 (pt) derivados de ciclohexanol espirocíclicos
DK1881967T3 (da) Substituerede benzo (D) isoaxol-3-yl-amin-forbindelser som analgetika
UY31502A1 (es) Proceso mejorado para sintetizar 5-cyclopentyl-5-11-dihydro-10-oxa-1-aza-dibenzo[a,d]cyclohepten-5-ol usando tmeda
CR10157A (es) Compuestos químicos
DOP2002000433A (es) 2-tio-3,5-diciano-4-fenil-6-aminopiridinas substituidas y su uso
CR10381A (es) Uso de bifenilamidas de acido arilcarboxilico para el tratamiento de semillas
BRPI0411268B8 (pt) processo para a preparação de compostos 3-aril butil-amina substituído
UY27571A1 (es) 2-tio-3, 5-diciano-4-fenil-6-aminopiridinas sustituidas y su uso
ECSP077271A (es) Derivados de pirimidina
ECSP077259A (es) Derivados de pirimidina
BRPI0908738A2 (pt) composto, medicamento, uso de um composto, e, processo para preparar os compostos
NO20081685L (no) Fremgangsmate for fremstilling oksazolidin-beskyttelse aminodolforbindelser anvendbare som mellomprodukter for Florfenicol
IN2012DN00411A (pt)
CR8357A (es) Derivados de tetrahidronaftaleno, procedimiento para su preparacion y su uso como antiinflamatorio
BRPI0713314A2 (pt) Processo para a preparação de 3-(2-hidróxi-5-fenil substituído)-n-alquil-3-fenilpropilaminas
NI200500164A (es) Nueva difenilazetidinona con caracteristicas fisiologicas mejoradas, correspondiente metodo de produccion, medicamentos que contienen dicho compuesto y su uso.
BRPI0913291A2 (pt) composto, pró-droga, medicamento, métodos para diminuir a proteína 4 ou tratamento de diabete em um mamífero, e, uso do composto
CR10540A (es) Derivados ciclopropil amina
BRPI0813438A2 (pt) Processo para preparar um composto, uso de um composto, e, composto.
ECSP088740A (es) Derivados de tetrahidronaftalina, procedimientos para prepararlos y su uso como antiinflamatorios
ECSP066540A (es) Pentanoles transpuestos, un método para prepararlos y su uso como antiinflamatorios
BRPI0507847A (pt) processo para a preparação de um composto, e, composto
HRP20080057T3 (en) 9,10-alpha,alpha-oh-taxane analogs and methods for production thereof
DE502005008057D1 (de) Substituierte cyclopenten-verbindungen
ECSP077306A (es) Derivados de alquiliden-tetrahidronaftaleno, procedimiento para su preparación y su uso como antiinflamatorios

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2260 DE 29/04/2014.